A common selective serotonin reuptake inhibitor and σ-1 receptor agonist, mounting data indicates that fluvoxamine prevents clinical deterioration in outpatients with acute COVID-19. This finding is…
Novavax, Inc. (Nasdaq: NVAX), a biotechnology company developing next-generation vaccines for serious infectious diseases, today announced its participation in a newly expanded investigator-initiated Phase 2…
A leading trial site organization has opened up a new site, now centering around a family practice in Lincoln, Nebraska. Lincoln Medical Education Partnership has been offering…
One of the largest vendors providing regulatory review solutions, research quality, compliance consulting services, and clinical site technologies, recently shared the publication of The State of Clinical…
The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, has established a network of research sites to study…
Canada, as pretty much every other Western country, hasn’t narrowed down a treatment for early onset COVID-19. TrialSite News has been extensively reporting on various…
Ian Chan of Abpro, addresses the important conversation about Covid-19 treatments and the race to catch up to mutant variants. The Boston based biotech Abpro…
GlaxoSmithKline announced the decision to halt the phase 2 INDUCE-3 and INDUCE-4 trials, which are evaluating its investigational inducible T cell co-stimulatory (ICOS) agonist feladilimab…
Sage Therapeutics and Biogen reported topline results from the Phase 2 KINETIC Study evaluating SAGE-324 in the treatment of patients with essential tremor (ET). The…
Kiniksa announced results from the Phase 2 portion of a phase 2/3 trial of mavrilimumab in non-mechanically ventilated patients (Cohort 1) with severe COVID-19 pneumonia…
Please confirm you want to block this member.
You will no longer be able to:
Please note: This action will also remove this member from your connections and send a report to the site admin. Please allow a few minutes for this process to complete.
